News
LGND
70.37
-0.89%
-0.63
Tourlite Capital Q1 2024 Investor Letter
Tourlite Capital Management, LP is an asset management firm focused on long/short equity investing in public companies. Tourlite Fund, LP returned 6.0% for the First Quarter of 2024. The Fund has annualized returns of 10.0%, compared to the S&P 500 and Russell 2000.
Seeking Alpha · 15h ago
Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study
NASDAQ · 2d ago
Press Release: Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
Ligand to Report First Quarter 2024 Financial Results on May 7, 2024. The company will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update. Ligand Pharmaceuticals will report first quarter 2024 financial results after the close of the U.S. Financial markets.
Dow Jones · 2d ago
Ligand Pharma (LGND) Gets a Buy from Barclays
TipRanks · 2d ago
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?
NASDAQ · 3d ago
Weekly Report: what happened at LGND last week (0415-0419)?
Weekly Report · 3d ago
Jazz Pharmaceuticals: Cheap But Complicated
Seeking Alpha · 04/18 17:26
Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up
NASDAQ · 04/18 13:44
Wall Street Analysts Predict a 45.56% Upside in Ligand (LGND): Here's What You Should Know
NASDAQ · 04/17 13:55
Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why
NASDAQ · 04/16 16:47
Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study
NASDAQ · 04/16 15:46
Corcept (CORT) Completes Enrollment in Phase II ALS Study
NASDAQ · 04/16 15:34
Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug
NASDAQ · 04/16 15:28
J&J sets guidance below consensus as MedTech underperforms
Johnson & Johnson sets guidance below consensus as MedTech underperforms in Q1 2024. The pharma giant's sales from its MedTech division fell short of Street forecasts. J&J shares slipped in the premarket after the results. The company revised its full-year 2024 revenue outlook below consensus.
Seeking Alpha · 04/16 11:20
Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why
NASDAQ · 04/15 17:01
Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors
NASDAQ · 04/15 16:54
Weekly Report: what happened at LGND last week (0408-0412)?
Weekly Report · 04/15 12:07
AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids
NASDAQ · 04/12 14:33
Ligand Pharmaceuticals Price Target Maintained With a $95.00/Share by Benchmark
Dow Jones · 04/12 13:24
Benchmark Reiterates Buy on Ligand Pharmaceuticals, Maintains $95 Price Target
Benzinga · 04/12 13:14
More
Webull provides a variety of real-time LGND stock news. You can receive the latest news about Ligand Pharma through multiple platforms. This information may help you make smarter investment decisions.
About LGND
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.